FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

 

For the month of March 2026 

 

Commission File Number: 001-11960

 

AstraZeneca PLC

 

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

 

 

 

AstraZeneca PLC

 

INDEX TO EXHIBITS

 

 

 20 March 2026

Notification of Admission of Further Securities to Trading (PRM 1.6.4R)

AstraZeneca PLC (the Company) announced today the following information in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R.

1	Details of the issuer
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
2	Details of the transferable securities admitted to trading
a)	Name, type and identification code	Ordinary Shares of $0.25 each   ISIN: GB0009895292
b)	Regulated market	London Stock Exchange - Main Market
c)	Number of further securities issued and admitted	45,750
d)	Total number of securities in issue following admission	1,550,980,332
e)	Fungibility	Fully fungible with existing Ordinary Shares
3	Admission details
a)	Date of admission	Issued between 20 January 2026 to 19 March 2026 (admitted under a block admission dated 29 January 2021)
b)	Prospectus information	Prospectus: N/A   Supplementary: N/A   Company's webpage: https://www.astrazeneca.com
c)	Coverage of notification	Admission of shares under the Company's employee share schemes from 20 January 2026 up to 19 March 2026, admitted to trading on the Main Market of the London Stock Exchange under the Company's existing block admission of shares dated 29 January 2021.

 

 

AstraZeneca 

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca 

 

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

 

Matthew Bowden

Company Secretary

AstraZeneca PLC

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

 

Date: 20 March 2026

	By: /s/ Matthew Bowden
	Name: Matthew Bowden
	Title: Company Secretary